SASRO
Scientific Association of Swiss Radiation Oncology

SGSMP
SSRPM
SSRFM

Program

2nd SASRO/SSRMP Joint Annual Meeting

20th Annual Meeting SASRO

50th Annual Meeting SSRMP

SASRO and SGSMP would like to thank all Companies and Sponsors !

alphabetical order

ACCURAY

SILVER SPONSOR

BAYER Science For A Better Life

BRAINLAB

Burgerstein Vitamine

CONMEDICA
High End Radiotherapy

MTC^C

C-RAD

MEDTECHCONSULTING.CH

COSSMANN

BRONZE SPONSOR

ELEKTA

ico cet

INNOMEDICUS

IntraOp

janssen
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

kaiku
Created by NETMEDI

MediTron

MERCK

MÖLNLYCKE HEALTH CARE

OPASCA

PHILIPS

PTW

QUALIFORMED

raditec
radiation & technology

RaySearch Laboratories

RTsafe

DR. SENNEWALD
medizintechnik gmbh

Sie - Rep GmbH
Hospital and X-Ray Accessories

SOLUMEDICS

SVMTRA / ASTRM
Schweizerische Vereinigung der Fachleute für med. tech. Radiologie
Association suisse des techniciens en radiologie médicale
Associazione svizzera per la tecnici di radiologia medica

GOLD SPONSOR

VARIAN medical systems

ZEISS

PLAN 3rd FLOOR

BOOTHS

01	VARIAN	13	SIEREP
02	KAIKU	14	MEDITRON
03	INNOMEDICUS	15	SOLUMEDICS
04	RADITEC	16	ZEISS
05	OPASCA	17	JANSSEN CILAG
06	ELEKTA	18	INTRAOP
07	RAYSEARCH	19	CONMEDICA
08	PHILIPS	20	BRAINLAB
09	MERCK	21	RT-SAFE
10	BURGERSTEIN	22	ACCURAY
11	MEDTECH	23	SVMTRA
12	PTW	24	ICOTEC
		25	MOELNLYCKE
		26	QUALIFORMED

Conference Rooms OST + WEST

SPEAKERS ROOM

POSTERS/NURSE SEMINARS 2nd FLOOR!

COFFEE / DRINKS

'HIT THE TARGET' - Event

GOLD SPONSOR VARIAN

SILVER SPONSOR BAYER

BRONZE SPONSOR ELEKTA

Scientific Committees

For Medical Physics

For SGSMP: Raphael Moeckli, Lausanne; Stefano Presilla, Bellinzona; Götz Kohler, Basel; Peter Manser, Berne

For SASRO: Giovanna Dipasquale, Geneva; Manfred Sassowsky, Inselspital, Berne

For Medical Radiation Oncology

Damien Weber, Villigen; Daniel Zwahlen, Chur; Gianfranco Pesce, Bellinzona; Paul Martin Putora, St. Gallen; Guenther Gruber, Zürich

For Radiation Biology

Yitzhak Zimmer, Inselspital, Berne

For RTTs

Sabine Krummenacher, Triemli; Arthur Sterchele, St. Gallen

For Nurses

Marianne Scharfenberger, Winterthur

Award Committees

SVMTRA Award

Ulrike Dechantsreiter, Lucerne; Arthur Sterchele, St. Gallen

Best Poster and Best Presentation Awards

For SGSMP: Goetz Kohler, Basel; Stefano Presilla, Bellinzona; Manfred Sassowsky, Berne

For SASRO: Oscar Matzinger, Vevey; Karl Beer, Biel

Abstracts available online

WISSENSBASIERTE PLANUNG



Steigern Sie die Qualität. Senken Sie die Häufigkeit von Wiederholungen.

Die wissensbasierte Planung von RapidPlan™ öffnet das Tor für die nächste Generation der individualisierten Bestrahlungsplanung. Ärzte können nun verschiedene Arten von Krebs behandeln, indem sie wissens-basierte Planung nutzen und anwenden.

Durch die Bereitstellung von vorkonfigurierten Modellen kann RapidPlan Kliniken helfen, Variabilität bei der Bestrahlungsplanung zu verringern. Dadurch kann erneut eine höhere Konsistenz, Effizienz und Qualität bei der Patientenversorgung erreicht werden.

Optimieren Sie Ihre Planung!

VARIAN
medical systems

Erfahren Sie mehr über die Vorteile von Eclipse unter
www.varian.com info.europe@varian.com

THURSDAY, 25th August, 2016

12:00 **Registration; Industrial Exhibition**

12:30 – 12:55 **Pre-Meeting Symposium (by Dr Sennewald) (Conference Room _OST)**

Welcome (G Sennewald, S Bodis)
Focussed high frequency antenna arrays: A hint at the future (P Turner, G Sennewald)
The Search for Evidence for Radiotherapy and Hyperthermia *and*
Swiss Clinical Trials for HT and RT (N Datta)
Swiss Hyperthermia Network and Swiss HT Tumorboard (S Bodis, E Puric)

13:00 – 13:15 **Opening Session (Conference Room _OST)**

R Boucenna, Lausanne; Congress President SSRMP

G Gruber, Zurich; Congress President SASRO

13:15 – 14:30 **SESSION 1 (Conference Room _OST): Combined 1**

Chairs: U Schneider, Zurich; A Papachristofilou, Basel

13:15 – 13:30 1.1 Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: A systematic review with conventional and network meta-analyses
NR Datta[1], S Rogers[1], D Klingbiel[2], S Gómez[1], E Puric[1], S Bodis[1,3], *[1]Centre for Radiation Oncology, KSA-KSB, Kantonsspital Aarau, Aarau, [2] Swiss Group for Clinical Cancer Research (SAKK), Coordinating Centre, Bern, [3] Department of Radiation Oncology, University Hospital, Zurich*

13:30 – 13:45 1.2 Can tracking be beneficial in SBRT pancreas treatments?
Karava K, Ehrbar S, Riesterer O, Roesch J, Glatz S, Klöck S, Guckenberger M, Tanadini-Lang S; *University Hospital Zurich (USZ), Department of Radiation Oncology, Zurich*

13:45 – 14:00 1.3 Dosimetry of FLAH irradiation for studies on the biological effect induced in normal brain and GBM
K Petersson[1], P Montay-Gruel[2,3], M Jaccard[1*], MC Vozenin [2,3], T Buchillier[1], JF Germond[1], F Bochud[1], J Bourhis[2], C Bailat[1]; *[1]Institute of Radiation Physics (IRA), [2]Department of Radiation Oncology, [3]Radio-oncology laboratory, Lausanne University Hospital, Lausanne, Switzerland*

14:00 – 14:15 1.4 Calculation of the "effective dose" delivered by IGRT in H&N and breast treatments
M Conrad[1,2], G Bolard[3], M Nowak[1], B De Bari[1], W Jeanneret[1], JF Germond[1], F Bochud[1], R Moeckli[1]; *[1]Institute of Radiation Physics, Lausanne University Hospital, Lausanne, [2]Université de Genève, Genève, [3]Clinique de Genolier, Genolier, Switzerland*

14:15 – 14:30 1.5 Impact of the radiation dose on hepatic perfusion evaluated using liver scintigraphy mebrofenin
B De Bari[1], Th Breuneval[1], M Zeverino[2], S Godin[1], J Prior[3], J Bourhis[1], R Moeckli[2], M Ozsahin[1]. *[1]Radiotherapy Department, [2]Medical Physics, [3]Service de Médecine Nucléaire, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland*

14:30 – 15:15 **Industrial Exhibition; Poster Exhibition; Coffee Break**

15:15 – 17:00 SESSION 2 (Conference Room _OST): Clinical 1

Chairs: F Herrera, Lausanne; K Zaugg, Berne

15:15 – 15:30 2.1 Impact of the radiation dose on the pulmonary perfusion assessed using lung scintigraphy
B De Bari[1], S Godin[1], M Zeverino[2], Th Breuneval[1], J Prior[3], Bourhis[1], R Moeckli[2], M Ozsahin[1]. *[1]Radiotherapy Department, [2]Medical Physics, [3]Service de Médecine Nucléaire, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland*

15:30 – 15:45 2.2 Non-resected and R1 resected pancreatic adenocarcinoma: Feasibility and patients' outcome after radio-chemotherapy with high dose external radiotherapy (RT)
D Lauffer[1], S Thalmann[1], P Kuhn[1], M Kueng[2], T Breuneval[1], PA Tercier[1], G Risse[1], B Egger[3], AS Allal[1]; *[1]Service de radio-oncologie, [2]Service d'oncologie, [3]Service de chirurgie, HFR- hôpital fribourgeois; Switzerland*

15:45 – 16:00 2.3 Long-term outcome of early stage glottic cancer treated with radiotherapy and/or surgery
M Shelan[1], E Mathier[1], L Anschütz[2], S Adrian[2], B Bojaxhiu[1], A Dal Pra[1], F Behrensmeier[1,3], M Caversaccio[2] DM Aebersold[1], R Giger[2], O Elicin[1]; *1 Department of Radiation Oncology and 2 Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, Switzerland, 3 Radiation-Oncology-Centre, Biel - Seeland - Berner Jura, Biel, Switzerland*

16:00 – 16:15 2.4 Impact of the site of metastasis on prostate cancer-specific survival in patients treated with curative radiotherapy
M Pascale[1], C Azinwi[2], G Pesce[2], E Roggero[1], F Stoffel[3], A Richetti[2]; *[1]Oncology Unit and [2]Radio-oncology Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona/Lugano, [3]Urology Unit, Ospedale San Giovanni, 6500 Bellinzona, Switzerland*

16:15 – 16:30 2.5 Risk Factors for PEG-Dependency and Unplanned Hospitalizations in Patients with Head and Neck Cancer Who Underwent Gastrostomy Tube Installment
BK Shrestha[1], B Bojaxhiu[1], O Elicin[1], A Dal Pra[1], A Macpherson[2], B Heimgartner[2], R Giger[3], DM Aebersold[1], K Zaugg[1]; *[1]Department of Radiation Oncology [2]Department of Visceral Surgery and Medicine, Division of Gastroenterology and [3]Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, Bern, Switzerland*

16:30 – 16:45 2.6 Dose-escalated salvage radiotherapy for histologically proven macroscopic recurrence after radical prostatectomy: Clinical outcomes and toxicity results
M Shelan, S Odermatt, B Bojaxhiu, O Elicin, DM Aebersold, A Dal Pra; *Department of Radiation Oncology, Inselspital, Bern University Hospital, Switzerland*

16:45 – 17:00 2.7 Safety and early efficacy of stereotactic radiosurgery in trigeminal neuralgia
Lavajo Vieira B[1] , Ares C[1], Dipasquale G[1], Nouet P[1], Bijlenga P[2], Miralbell R[1]; *[1]Department of Radiation Oncology, [2]Department of Neurosurgery, University Hospital of Geneva, Geneva, Switzerland*

15:15 – 17:00 SESSION 3 (Conference Room _WEST): Physics 1

Chairs: L Wilke, Zurich; Y Kaeser, Zurich

15:15 – 15:30 3.1 Liquid filled ionization chamber 2D-array for patient specific QA for stereotactic treatment at CyberKnife®
V Magaddino, V Vallet, D Patin**Fehler! Textmarke nicht definiert.**, M Schopfer**Fehler! Textmarke nicht definiert.**, R Moeckli; *Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland*

15:30 – 15:45 3.2 Evaluating the actual direction distribution of the primary radiation for a Cyberknife-M6 using system log files
D Henzen[1], CC Zanella[1,2], D Schmidhalter[1], W Volken[1], PH Mackeprang[1], M Malthaner[1], MK Fix[1], P Manser[1]; *[1]Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, [2]Institute for Biomedical Engineering, ETH and University of Zürich, Zürich, Switzerland*

15:45 – 16:00 3.3 Monte Carlo model of a gantry for proton pencil beam scanning
C Winterhalter[1], S Safai[1], C Grassberger[2], D Oxley[1], DC Weber[1], T Lomax[1]; *[1]Center for Proton Therapy, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland, [2]Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA*

16:00 – 16:15 3.4 Dose and energy measurements in radiotherapy by a combination of TLD100 and TLD100H
P Hauri, U Schneider; *Faculty of Science, Universtiy of Zurich, Zurich, Switzerland, Radiotherapy Hirslanden, Hirslanden Medical Center, Aarau, Switzerland*

16:15 – 16:30 3.5 Comparison of two automated treatment planning solutions for complex head and neck cancer
M Zamburlini[1], J Krayenbuehl[1], S Graydon[1], I Norton[2], G Studer[1], S Kloeck[1], M Guckenberger[1]; *[1]University Hospital Zurich, Department of Radiation and Oncology, Zurich, Switzerland, [2]Philips Radiation Oncology Systems, Fitchburg, Wisconsin, USA*

16:30 – 16:45 3.6 Concepts and principles of deformable image registration QA
JF Germond, R Moeckli; *Institute of Radiation Physics Lausanne University Hospital, Lausanne, Switzerland*

16:45 – 17:00 3.7 Comparison of two deformable registration software using an in-house “deformable phantom”
N Koutsouvelis, M Rouzaud; *Radiation therapy department, Geneva University Hospital, Geneva, Switzerland*

17:00 – 18:30 SRO General Assembly (Conference Room _OST)

17:00 – 18:30 SSRMP General Assembly (Conference Room _WEST)

XOFIGO® ist indiziert für die Behandlung von Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) und symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen.[1*]

Verschreiben Sie Xofigo® bei den ersten Anzeichen einer Progression unter einer neuartigen Antihormontherapie

- Xofigo® verlängert das mediane Gesamtüberleben im Vergleich zum besten Therapiestandard allein auf 14,9 Monate.[2]

* Bei nicht orchiektomierten Patienten soll eine antiandrogene Behandlung zur Suppression des Testosteronspiegels auf Kastrationsniveau weitergeführt werden.

1. Fachinformation Xofigo® (Radium-223-Dichlorid), www.swissmedicinfo.ch. **2.** Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine 2013;369:213

Gekürzte Fachinformation XOFIGO®

Wirkstoff: Radium Ra-223-Dichlorid. **Indikation:** Xofigo ist indiziert für die Behandlung von Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) und symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen. Bei nicht orchiektomierten Patienten soll eine antiandrogene Behandlung zur Suppression des Testosteronspiegels auf Kastrationsniveau weitergeführt werden. **Dosierung/Anwendung:** 6 Injektionen mit jeweils 55 kBq pro kg Körpergewicht in Abständen von 4 Wochen. Für die Anwendung bei Kindern, Jugendlichen und bei Frauen besteht keine Indikation. Xofigo ist ein Radiotherapeutikum. Anwendung nur durch autorisiertes Personal mit entsprechender Bewilligung des Bundesamtes für Gesundheit. **Kontraindikationen:** Schwangerschaft, Frauen, die schwanger sein könnten, Stillzeit. **Warnhinweise/Vorsichtsmassnahmen:** Knochenmarksuppression, vor Beginn der Behandlung und vor jeder weiteren Dosis muss eine hämatologische Untersuchung durchgeführt werden. Nicht untersucht bei Patienten mit Morbus Crohn oder Colitis ulcerosa. Bei Rückenmarkskompression vor Beginn oder Wiederaufnahme der Behandlung mit Xofigo eine der klinischen Indikation entsprechende Standardbehandlung durchführen. Knochenfrakturen vor Beginn oder Wiederaufnahme der Behandlung mit Xofigo orthopädisch stabilisieren. Unerwünschte Wirkungen auf Hoden und Spermien möglich, zuverlässige Kontrazeption notwendig. **Unerwünschte Wirkungen:** Sehr häufig: Thrombozytopenie, Diarrhoe, Erbrechen, Übelkeit. Häufig: Neutropenie, Panzytopenie, Leukopenie, Reaktionen an der Injektionsstelle. Gelegentlich: Lymphopenie **Interaktionen:** Sicherheit und Wirksamkeit einer Kombinationsbehandlung mit Xofigo plus Chemotherapie sind nicht untersucht, Wirkungen bezüglich Knochenmarksuppression können sich addieren. **Packungen:** 1 Injektionsflasche à 6 ml Lösung mit 6600 kBq. Verkaufskategorie A **Zulassungsinhaberin:** Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zürich. Ausführliche Information auf www.swissmedicinfo.ch.
L.CH.MKT.ONC.01.2016.0358-DE/EN/FR/IT

L.CH.MKT.ONC.06.2016.0412-DE/FR/IT

Xofigo®
Radium-223-dichlorid

FRIDAY, 26th August, 2016

07:30 **Registration**

08:00 – 09:00 **Industrial Exhibition (Exhibition Pass – 'Win an iPad'); Poster Exhibition**

08:00 – 08:30 **Refresher Course 1 (Conference Room _OST)**

a 25' Radiotherapy in prostate cancer: More dose, less fractions?

A Dal Pra, *Inselspital and University Hospital, Bern, Switzerland*

08:00 – 08:30 **Refresher Course 2 (Conference Room _WEST)**

a 25' Hit the right target: PET-CT and MRI in treatment planning

HJ Vees, *Klinik Hirslanden, Zürich, Switzerland*

08:30 – 08:55 **RTsafe Symposium (Conference Room _OST)**

a 25' Confidence building and peace-of-mind that you effectively 'Hit the Target' in cranial and spine SRS – Pseudo-in-vivo individualized dosimetry by RTsafe

E Pappas, *Founding Chairman and Chief Scientific Officer RTsafe, Greece*

09:00 – 10:15 **SESSION 4 (Conference Room _OST): Clinical 2**

Chairs: MC Valli, Bellinzona; L Plasswilm, St. Gallen

09:00 – 09:15 4.1 Timing of radiotherapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: long term results from IBCSG Trials VI and VII

P Karlsson[1]; BF Cole[2]; KN Price[3], RD Gelber[4]; AS Coates[5]; A Goldhirsch[6]; M Castiglione[7]; M Colleoni[8]; G Gruber[9]; *[1]Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden, [2]Department of Mathematics and Statistics, University of Vermont, Burlington, USA, [3]IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Boston, USA, [4]IBCSG Statistical Center, Department of Biostatistics and Computatonal Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard TF Chan School of Public Health, Boston, USA, [5]IBCSG and University of Sydney, Sydney, Australia, [6]Program for Breast Health (Senology), European Institute of Oncology and IBCSG, Milan, Italy, [7]IBCSG, Bern, Switzerland, [8]Division of Medical Senology, European Institute of Oncology and IBCSG, Milan, Italy, [9]Institute of Radiotherapy, Klinik Hirslanden, Zürich, Switzerland*

09:15 – 09:30 4.2 Hit the "lung" target: IOSI experience

F Martucci[1], S Cima[1], P Fanti[1], MC Valli[1], G Pesce[1], C Azinwi[1], K Yordanov[1], B Muoio[1], S Presilla[2], A Richetti[1]; *[1]Radiation Oncology,Oncology Institute of Southern Switzerland, Bellinzona-Lugano, [2]EOC, Medical Physics Unit, Bellinzona, Ticino; Switzerland*

09:30 – 09:45 4.3 Prognostic factors in breast cancer associated with brain metastases

O Santa Cruz[1], P Tsoutsou[1], S Anchisi[2], K Khanfir[3], L Negretti[4], C Girardet[5], O Ozsoy[3], M Ozsahin[6]; *[1]Radiation Oncology, Hopital Neuchatelois, La Chaux-De-Fonds, [2]Medical Oncology, Centre Hospitalier du Valais Romand (CHVR), Sion, [3]Radiation Oncology, Centre Hospitalier du Valais Romand (CHVR), Sion, CH, [4]Radiation Oncology, Clinica Luganese Moncucco, Lugano, [5]Pathology, Centre Hospitalier du Valais Romand (CHVR), Sion, [6]Radiation Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland*

09:45 – 10:00 4.4 Oligorecurrent nodal prostate cancer: long term results of an elective nodal irradiation approach

S Tran, T Falco, G Lamanna, L Lestrade, R Miralbell, T Zilli; *Radiation Oncology, Geneva University Hospital, Geneva, Switzerland*

10:00 – 10:15 4.5 Miss the target in old age breast cancer patients: the experience of the Ticino Breast Unit
S Cima[1,3], B Muoio[1], P Fanti[1,3], A Richetti[1,3], A Vanetti[2,3], C Canonica[2,3], C Azinwi[1], F Martucci[1], K Yordanov[1], G Pesce[1], MC Valli[1,3]; *[1] Radiation Oncology,Oncology Institute of Southern Switzerland, Bellinzona-Lugano, [2]Gynaecology Department, Ospedale Regionale Bellinzona e Valli, Bellinzona, [3]Centro di Senologia della Svizzera Italiana (CSSI), Switzerland*

10:15 – 10:45 Industrial Exhibition; Poster Exhibition; Coffee Break

10:45 – 12:00 SESSION 5 (Conference Room _OST): Combined 2

Chairs: Th Zilli, Geneva, M Aspradakis, Lucerne

10:45 – 11:00 5.1 Comparison of MLC and couch tracking for SBRT prostate cancer
S Schmid[1,2], S Ehrbar[1,3], S Klöck[1,3], M Guckenberger[1,3], S Tanadini-Lang[1,3]; [1]University Hospital Zurich, *Department of Radiation Oncology, Zürich, [2]ETH Zürich, Department of Physics, Zurich, [3]University of Zurich, Faculty of Science, Zurich, Switzerland*

11:00 – 11:15 5.2 Prospective study on the clinical impact of ^{18}F-fluorocholine (FCH) PET/CT on treatment management in biochemical recurrent prostate cancer: hit the right target for the right patient
B Muoio, C Azinwi, G Pesce, F Martucci, S Cima, MC Valli, P Fanti, K Yordanov, A Richetti ; *Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona-Lugano; Switzerland*

11:15 – 11:30 5.3 The breath hold method to reduce the heart dose for left sided breast radiotherapy
C Tamburella, J Abel, G Guibert, L Pion, O Santa Cruz, J Trouillot, M Voelin, P Weber, P Tsoutsou; *Hopital Neuchatelois, La chaux de Fonds, Switzerland*

11:30 – 11:45 5.4 Intraindividual comparison of 11C-Acetate and 18F-Fluorocholine PET/CT and PET/MRI studies for early recurrent prostate cancer after primary treatment
G Lamanna[1,2], V Garibotto[3,4], C Tabouret-Viau[3], O Rager[3], S Jorcano[5], HJ Vees[1], Y Seimbille[3], H Zaidi [3,4], O Ratib[3,4], F Buchegger [3,4], R Miralbell[1,4,5], T Zilli[1,4]; *[1]Radiation-Oncology, University Hospital of Geneva, Geneva, Switzerland, [2]Radiation-Oncology, IRCCS San Martino - IST National Cancer Research Institute, Genoa, Italy, [3]Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland, [4]Faculty of Medicine, Geneva University, Geneva, Switzerland, [5]Radiation Oncology, Teknon Oncologic Institute, Barcelona, Spain*

11:45 – 12:00 5.5 Potential of computed tomography with iterative metal artifact reduction algorithm for proton therapy of patients with metal implants
S Belloni[1,2], M Peroni[2], A Bolsi[2], T Niemann[3], D Engelhardt[3], N Fachouri[2], R Perrin[2], M Walser[2], G Fattori[2], RA Kubik-Huch[3], AJ Lomax[2], and DC Weber[2,4,5]; *[1]Department of Physics and Astronomy, University of Bologna, Italy, [2]Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland, [3]Department of Radiology, Cantonal Hospital Baden, Baden, Switzerland, [4]Radiation Oncology Inselspital, Bern, Switzerland, [5]Radiation Oncology, University Hospital of Zurich, Switzerland*

08:30 – 10:00 General Assembly IG Pflege RAO (Conference Room _WEST)

10:30 – 12:00 SESSION 6 (Conference Room _WEST): Nursing

Chairs: D. Miletic, Zürich; A. Stier, Zurich

a 30' 6.1 Krebs? Das Krebstelefon ist da mit Wissen und Fürsorge
A Zahno, Leiterin Krebstelefon, *Krebsliga Schweiz, Switzerland*

a 45' 6.2 Evidenzbasierte Pflege – Entzauberung der Wissenschaft
A Gutierrez, *Klinik Hirslanden, Aarau, Switzerland*

12:00 – 14:00 **Workshop MOELNLYCKE; Registration directly at Booth 25**

12:00 – 12:45 **Industrial Exhibition; Lunch; Poster Exhibition**

12:45 – 14:15 **LUNCH SYMPOSIA Conference Room _OST**

12:45 – 13:40 **VARIAN – GOLD SPONSOR**

Transforming Knowledge into Action

RapidPlan™ Knowledge Based Planning: an Innovative Tool for Modern Radiotherapy
A Fogliata, *Humanitas Research Hospital and Cancer Center, Milan, Italy*

Preliminary experience of Adaptive Radiotherapy simulations with the new Velocity platform
E Cagni, *IRCCS–ASMIN, Institute in advanced technologies and models of care in oncology, Reggio Emilia, Italy*

13:45 – 14:15 **BAYER – SILVER SPONSOR**

Radium-223 in castration-resistant prostate cancer: A radiation oncologist's perspective
M Sumila*, Klinik Hirslanden, Zurich, Switzerland*

12:45 – 14:15 **LUNCH SYMPOSIA Conference Room _WEST**

12:45 – 13:10 **MERCK**

10 Years Immunotherapy in Head & Neck Cancer – Concurrent systemic treatment and radiotherapy in locally advanced SCC
J Bourhis*, CHUV, Lausanne, Switzerland*

13:15 – 13:40 **BRAINLAB**

Brain Mets Planning and ETX

Stereotactic Radiosurgery Developments in the Treatment of Brain Metastases
Th Gevaert, *UZ Brussel, Brussels, Belgium*

13:45 – 14:10 **ACCURAY**

Accuray Last Breaking News
S Reid*, Product Marketing Manager, Accuray*

14:30 – 15:30 **SESSION 7 (Conference Room _OST): Combined 3**

Chairs: S Bulling, Eaux-Vives, N Andratschke, Zurich

14:30 – 14:45 7.1 Prone breast automatic segmentation of organs at risk including heart and coronary vessels: similarity indexes, contouring times and dose volume parameters
X Wang*[1], G Dipasquale*, V Chatelain-Fontanella*, O Fargier-bochaton*, R Miralbell*
** Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland, [1]Department of Radiation Oncology, Tianjin Union Medical Center, Tianjin, China*

14:45 – 15:00 7.2 Estimation of late effects for MERT and photon plans in radiotherapy of the breast and chest wall
A Joosten, S Müller, D Henzen, W Volken, D Frei, K Lössl, P Manser, MK Fix; *Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Switzerland*

15:00 – 15:15 7.3 PET/CT-guided SIB-IMRT Combined with Concurrent 5-FU/MMC for the Treatment of Anal Cancer: a Single Institution Experience
J Beer, M Zimmermann, D Zwahlen, C Oehler; Department of Radiation Oncology, Kantonsspital Graubünden, Chur, Switzerland

15:15 – 15:30 7.4 Radiomics of CT perfusion maps
M Nesteruk[1], O Riesterer[1], R Bundschuh[4], P Veit-Haibach[2,3], M Hüllner[2], G Studer[1], S Stieb[1], S Glatz[1], M Pruschy[1], M Guckenberger[1], S Tandini-Lang[1]; *[1]Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland, [2]Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Switzerland, [3]Department of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland, [4]Department of Nuclear Medicine, University Hospital Bonn, Germany*

14:30 – 15:30 SESSION 8 (Conference Room _WEST): RTT

Chairs: S. Berweger, Winterthur; Ch. Winter, Chur

14:30 – 14:42 8.1 Clinical implementation of an optical surface monitoring system (OSMS ®, VARIAN) in breast irradiation
A Tini, I Pytko, S Lang, C Winter, M Guckenberger, C Linsenmeier; *Department of Radiation Oncology, University Hospital Zürich, Switzerland*

14:42 – 14:54 8.2 Stability in positioning for lung radiosurgery (SBRT) patients
S Roosenthaler, S Khan, L Vugts, G Lutters, S Bodis, E Rabe; *Radio-Onkologie Zentrum KSA-KSB, Kantonsspital Aarau, Switzerland*

14:54 – 15:06 8.3 Validation of patient preparation and setup verification in SBRT for liver tumors – Case report
Panizza D[1], Colleoni P[1], Yordanov K[2], Valli MC[2], Pupillo F[1], Gaudino D[1], Moretto S[2], Rottoli G[2], Presilla S[1], Richetti A[2]; *[1]Ente Ospedaliero Cantonale, Medical Physics Unit, Bellinzona, Switzerland; [2]Oncology Institute of Southern Switzerland, Radiation Oncology Unit, Bellinzona-Lugano, Switzerland*

15:06 – 15:18 8.4 Multi radiotherapy modalities treatment for multi targets in malignant pheochromocytoma setting – case report
Soares Rodrigues J[1], Durham A[1], Leal S[1], Zulliger C[1], Patin D[2], Ozsahin M[1], Bourhis J[1]; *[1]Department of Radiation Oncology, CHUV and University of Lausanne, Lausanne, Switzerland; [2]Institute of Radiation Physics, CHUV and University of Lausanne, Lausanne, Switzerland*

15:18 – 15:30 8.5 Hypofractionated stereotactic radiotherapy feedback for the treatment of liver tumors using backup gating and auto hold beam
A Guerreiro, E Wyniger, A Dubouloz, R Miralbell, T Zilli, L Lestrade*; HUG Radio-Oncologie, Geneva, Switzerland*

14:30 – 15:30 Seminar 1 – Nursing (Seminar room – 2nd floor)

6.3 Natürlich essen während der Strahlentherapie – Vortrag mit Kostproben
E. Fischer, Autorin von Kochbüchern und Essensratgebern, *Wien, Österreich*

15:30 – 16:00 Industrial Exhibition; Poster Exhibition; Coffee Break

15:30 – 16:30 Workshop MOELNLYCKE; Registration directly at Booth 25

16:30 – 17:00 Seminar 2 – Nursing (Seminar room – 2nd floor)

6.4 Mepitel Film vs standard treatments for the prevention and cure of skin toxicity in postoperative treatment of breast cancer: a phase III study
G. Presta, A Puliatti; D Valcarenghi, S Cima, A Richetti, R Guggiari, MC Valli. *IOSI, Bellinzona, Switzerland*

16:00 – 17:15 SESSION 9 (Conference Room _OST): Physics 2

Chairs: A Bolsi, Villigen, F Verdun, Lausanne

16:00 – 16:15 9.1 Implementation of a complete time-effective dosimetric verification system for the commissioning and routine verification of Multiple Metastases Element (BrainLab)
S Alonso-Arrizabalaga, N Lomax, Z Girbau-Garcia, J McNamara, S Rogers, G Lutters, S Bodis; *RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland*

16:15 – 16:30 9.2 Bench-marking an automated planning tool for multiple brain metastases against an established multiple isocenter dynamic conformal arc technique
N Lomax, S Alonso, J McNamara, S Rogers, G Lutters, S Bodis; *Radio-Onkologie-Zentrum KSA-KSB, Kantonsspital Aarau, Switzerland*

16:30 – 16:45 9.3 High dose-per-pulse electron beam dosimetry – A saturation model for the Advanced Markus ionization chamber
K Petersson[1], M Jaccard[1], JF Germond[1], T Buchillier[1], F Bochud[1], J Bourhis[2,3], MC Vozenin[2,3], C Bailat[1]; *[1]Institute of Radiation Physics (IRA), Lausanne University Hospital, Lausanne, [2]Department of Radiation Oncology, Lausanne University Hospital, Lausanne, [3]Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland*

16:45 – 17:00 9.4 Electron dosimetry with Gafchromic EBT3 films: energy and dose-rate dependence
M Jaccard[1], K Petersson[1], T Buchillier[1], JF Germond[1], T Duran Ramiro[1], MC Vozenin[2,3], J Bourhis[2,3], F Bochud[1], C Bailat[1]; *[1]Institute of Radiation Physics (IRA), Lausanne University Hospital, Lausanne, [2]Department of Radiation Oncology, Lausanne University Hospital, Lausanne, [3]Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital Lausanne, Switzerland*

17:00 – 17:15 9.5 Comparison of photon MLC and cut-out collimated electron beams for standard electron treatments
S Müller[1], MK Fix[1], D Henzen[1], D Frei[1], D. Frauchiger[1], K Lössl[1], MFM Stampanoni[2], P Manser[1]; *[1]Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, [2]Institute for Biomedical Engineering, ETH Zürich and PSI, Villigen, Switzerland*

16:00 – 17:15 SESSION 10 (Conference Room _WEST): Radiobiology

Chairs: M. Medovà, Bern; M. Pruschy, Zurich

16:00 – 16:25 I.1 'HIT THE TARGET': The biologist's perspective

Invited speaker: S. Rottenberg, Berne; Switzerland

16:25 – 16:37 10.1 The role of the MET receptor tyrosine kinase in tumor resistance to radiation therapy: a phosphoproteomic approach
E Orlando[1,2], A Bensimon[2], M Medovà[1], DM Aebersold[1], R Aebersold[2], Y Zimmer[1]; *[1]Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland, [2]Institute of Molecular Systems Biology, ETH Zürich, Switzerland*

16:37 – 16:49 10.2 Involvement of MET signaling in the HIF-1alpha pathway
A Glück[1,2], M Medová[1,2], A Quintin[1,2], E Orlando[1,2], D Leiser[1], DM Aebersold[1,2], Y Zimmer[1,2]; *[1]Department of Radiation Oncology, Inselspital, [2]Department of Clinical Research, Radiation Oncology, University of Bern, Bern, Switzerland*

16:49 – 17:01 10.3 Regulation of the Oncogene Carnitine Palmitoyltransferase 1C under hypoxia involves HIF1 alpha and p53
N Chang, D Dudka, DM Aebersold, J Feng, K Zaugg; *Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*

17:01 – 17:13 10.4 Dose-Rate Effect of Novel Radiation Technologies: Relevance for the Clinical Use
D Dudka, N Chang, J Feng, K Zaugg; *Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*

17:15 – 18:30 **General Assembly SASRO (Conference Room _OST)**

18:45 / 19:15 **Bus transfer to Social Dinner at Water Castle Wyher (with ticket only)**

19:30 – 20:00 **Apero**

20:00 **Dinner**



VERSA HD
MEETS ITS PERFECT MATCH

Versa HD

The powerful combination of Versa HD™ and Monaco® delivers a unique blend of unrivaled dose delivery and intelligent dose planning. With the ultra-low transmission of Agility™ and Monaco's Monte Carlo accuracy, dose delivery to the target can be precisely controlled while ensuring surrounding anatomy is protected. Together, they make dynamic and stereotactic techniques not only possible but routine practice. GO BEYOND with Versa HD and Monaco.

VISIT VERSAHD.COM

ELEKTA

451337 114 39 Rev03.16

SATURDAY, 27th August, 2016

07:45 – **Registration**

08:15 – 10:15 **Symposium 'HIT THE TARGET' (Conference Room)**

Chairs: D. Weber, Villigen, SASRO President; P. Manser, Bern, SSRMP President

08:15 – 08:45 HIT THE TARGET: The medical physicist's perspective

a 25' I.2 Invited speaker: W. Verbakel, *Amsterdam, The Netherlands*

08:45 – 09:15 HIT THE TARGET: Staffing/Education/Quality

a 25' I.3 Invited speaker: M. Coffey, *Dublin, Ireland*

09:15 – 09:45 HIT THE TARGET: High dose to the target

a 25' I.4 Invited speaker: M. Guckenberger, *Zürich, Switzerland*

09:45 – 10:15 HIT THE TARGET: Radioimmunotherapy

a 25' I.5 Invited speaker: F. Lohr, *Modena, Italy*

10:15 – 11:00 **Industrial Exhibition; Poster Exhibition; Coffee Break**

11:00 – 12:30 **SESSION 11 (Conference Room): Combined 4**

Chairs: D Zwahlen, Chur, S Kloeck, Zürich

11:00 – 11:15 11.1 Prevention of acute dermatitis with Noviphenone®, a proprietary Camellia Sinensis extract, in female patients with breast cancer undergoing adjuvant radiotherapy
G Naef[1], UE Gasser[2], HE Holzgang[3], DR Zwahlen[1], *[1] Department of Radiation Oncology, Kantonsspital Graubünden, Chur; [2] ClinResearch LTD, Aesch; [3] Novelpharm AG, Schlieren; Switzerland*

11:15 – 11:30 11.2 ITV, MidV, gating or tracking - what to use when?
S Ehrbar[1,2], A Tartas[1,3], S Stark[1,2], O Riesterer[1,2], S Klöck[1,2], M Guckenberger[1,2], S Tanadini-Lang[1,2]; [1]*Department of Radiation Oncology, University Hospital Zurich, Zürich, [2]University of Zürich, Faculty of Science, Zürich, Switzerland, [3]University of Warsaw, Faculty of Physics, Warsaw, Poland*

11:30 – 11:45 11.3 Combination of Stereotactic Radiotherapy and Targeted Therapy: Patterns-of-care Survey among Swiss and German Clinics
SGC Kroeze[1], C Fritz[1], N Andratschke[1], U Nestle[2], T Brunner[2], M Guckenberger[1]; *[1]University Hospital Zürich, Department of Radiotherapy, Switzerland; [2]University Hospital Freiburg, Department of Radiotherapy, Germany*

11:45 – 12:00 11.4 Clinical commissioning of MR-Only Prostate treatment planning workflow
G Bolard, S Bulling, N Hejira; *Clinique de Genolier, Switzerland*

12:00 – 12:15 11.5 Reducing treatment delivery times in prostate cancer robotic SBRT
PH Mackeprang[1], D Terribilini[1], E Herrmann[2], O Elicin[2], A Jensen[2], D Henzen[1], D Schmidhalter[1], M Malthaner[1], S Angelmann[2], S Fankhauser[2], MK Fix[1], P Manser[1], DM Aebersold[2], A Dal Pra[2]; *[1]Division of Medical Radiation Physics and [2]Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*

12:15 – 12:30 11.6 Radiotherapy infrastructure and human resources in Switzerland – Present status and its projected computations for 2020

NR Datta[1], S Khan[1], D Marder[1], D Zwahlen[2], S Bodis[1,3]; *[1]RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Aarau; [2]Department of Radiotherapy, Kantonsspital Graubünden, Chur; [3]Department of Radiation Oncology, University Hospital Zurich*

12:30 – 12:50 **Awards, 'Win an iPad'; 'Hit the Target' (Conference Room)**

Moderator: G Gruber

12:50 – 13:00 **FAREWELL (Conference Room)**

P Manser (President SSRMP)

D Weber (President SASRO)


STRAHLENTHERAPIE
RADIOTHERAPY
4.0
initiated by
OPASCA
„By providing advanced holistic information systems for clinical workflows, we are changing the way of treatment in radiotherapy to make processes safer, more efficient and patient-centered.“
– Dr. Alexej Swerdlow
Founder and CEO of OPASCA
Visit OPASCA at SASRO Meeting 2016 | 3rd floor | booth 05

SASRO
Scientific Association of Swiss Radiation Oncology

SGSMP
SSRPM
SSRFM

Thanks for your participation and see you next year!